TRIM28 haploinsufficiency predisposes to Wilms tumor.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 08 2019
Historique:
received: 08 10 2018
revised: 08 12 2018
accepted: 15 01 2019
pubmed: 30 1 2019
medline: 4 12 2019
entrez: 30 1 2019
Statut: ppublish

Résumé

Two percent of patients with Wilms tumors have a positive family history. In many of these cases the genetic cause remains unresolved. By applying germline exome sequencing in two families with two affected individuals with Wilms tumors, we identified truncating mutations in TRIM28. Subsequent mutational screening of germline and tumor DNA of 269 children affected by Wilms tumor was performed, and revealed seven additional individuals with germline truncating mutations, and one individual with a somatic truncating mutation in TRIM28. TRIM28 encodes a complex scaffold protein involved in many different processes, including gene silencing, DNA repair and maintenance of genomic integrity. Expression studies on mRNA and protein level showed reduction of TRIM28, confirming a loss-of-function effect of the mutations identified. The tumors showed an epithelial-type histology that stained negative for TRIM28 by immunohistochemistry. The tumors were bilateral in six patients, and 10/11 tumors are accompanied by perilobar nephrogenic rests. Exome sequencing on eight tumor DNA samples from six individuals showed loss-of-heterozygosity (LOH) of the TRIM28-locus by mitotic recombination in seven tumors, suggesting that TRIM28 functions as a tumor suppressor gene in Wilms tumor development. Additionally, the tumors showed very few mutations in known Wilms tumor driver genes, suggesting that loss of TRIM28 is the main driver of tumorigenesis. In conclusion, we identified heterozygous germline truncating mutations in TRIM28 in 11 children with mainly epithelial-type Wilms tumors, which become homozygous in tumor tissue. These data establish TRIM28 as a novel Wilms tumor predisposition gene, acting as a tumor suppressor gene by LOH.

Identifiants

pubmed: 30694527
doi: 10.1002/ijc.32167
doi:

Substances chimiques

DNA, Neoplasm 0
TRIM28 protein, human EC 2.3.2.27
Tripartite Motif-Containing Protein 28 EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

941-951

Informations de copyright

© 2019 UICC.

Auteurs

Illja J Diets (IJ)

Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands.
Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.

Juliane Hoyer (J)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.

Arif B Ekici (AB)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.

Bernt Popp (B)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.

Nicoline Hoogerbrugge (N)

Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands.
Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.

Simon V van Reijmersdal (SV)

Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Rajith Bhaskaran (R)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Michel Hadjihannas (M)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.

Georgia Vasileiou (G)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.

Christian T Thiel (CT)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.

Didem Seven (D)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.
Department of Medical Biology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.

Steffen Uebe (S)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.

Denisa Ilencikova (D)

Department of Pediatrics, Children's University Hospital, Comenius University, Bratislava, Slovakia.

Esmé Waanders (E)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Annelies M C Mavinkurve-Groothuis (AMC)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Nel Roeleveld (N)

Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands.
Department of Pediatrics, Radboudumc Amalia's Children's Hospital, Nijmegen, The Netherlands.

Ronald R de Krijger (RR)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Jenny Wegert (J)

Theodor-Boveri-Institute/Biocenter, Developmental Biochemistry, and Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.

Norbert Graf (N)

Department of Pediatric Hematology and Oncology, Saarland University, Medical Center Homburg/Saar, Homburg, Germany.

Christian Vokuhl (C)

Kiel Pediatric Tumor Registry, Section of Pediatric Pathology, Department of Pathology, Christian Albrechts University, Kiel, Germany.

Abbas Agaimy (A)

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Manfred Gessler (M)

Theodor-Boveri-Institute/Biocenter, Developmental Biochemistry, and Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.

André Reis (A)

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Institute of Human Genetics, Erlangen, Germany.

Roland P Kuiper (RP)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Marjolijn C J Jongmans (MCJ)

Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands.
Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.

Markus Metzler (M)

Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH